All News

COVID-19 vaccination significantly reduces long-term mortality risk in chronic obstructive pulmonary disease patients, highlighting its importance for respiratory health and safety.

The administration announces back-to-back approvals for oral therapies used to treat uncomplicated urogenital gonorrhea.

Susan Thomas, RN, CCO at LucyRx, explained the unique offerings from a newly introduced women’s health benefit program launched on January 1, 2026.

Although several vaccines are still being recommended, a variety of those protecting against respiratory viruses and other diseases have been narrowed on child vaccine schedules.

FDA approves denosumab biosimilars Boncresa and Oziltus, enhancing access to affordable treatments for osteoporosis and oncology-related conditions.

The company announces that the pill is now available at over 70,000 pharmacies across the country.

Pharmacists are transforming reproductive health care by expanding their roles in contraception and patient support, despite facing significant barriers.

Orforglipron shows promise in maintaining weight loss for those transitioning from injectable GLP-1 therapies, offering a convenient oral alternative.

FDA approves tradipitant, a treatment for motion sickness, offering effective prevention after 40 years without new options.

Jennifer Flynn, CPHRM, joins Drug Topics to discuss the nuances in social media use for pharmacists and the potential risks they can encounter.

Explore the latest insights on team-based care, AI in pharmacy, and innovative PBM models shaping the future of health care in 2025.

Spanning those focused on pneumococcal diseases to continued developments of vaccines against COVID-19, these are the most-read immunization stories from 2025.

Pharmacy benefit manager reforms and new pain management options reshape the pharmaceutical landscape, enhancing patient access and care in 2025.

With brand-new challenges and opportunities in the GLP-1 space and obesity management as a whole, here are the top developments from the past year.

Marking 5 years since the COVID-19 pandemic forever changed health care in 2020, check out the top 5 COVID-19 stories from 2025.

Explore the latest advancements in pharmacy, including innovative therapies, cost-saving models, and significant reforms shaping the industry in 2025.

A recent study reveals COVID-19 vaccination significantly reduces severe maternal disease and preterm birth risks during pregnancy.

Discover critical insights on respiratory health, COVID-19 impacts, and vaccination strategies from recent studies and regional policy changes.

OTC access expands, enhancing reproductive health and migraine relief while raising safety concerns about online pharmacies and medications like Benadryl.

The top pneumococcal stories of 2025 explored the evolving landscape of pneumococcal vaccination.

The landmark oral formulation of the popular weight loss drug is set to launch in early 2026.

Kenric B. Ware, PharmD, MBA, AAHIVP, addresses the pharmacist’s role in addressing HIV stigma and providing public health services for patients with the virus.

The top women's health stories in 2025 included groundbreaking advancements in women's health against an alarming mortality trend.

Personalized insulin management and small lifestyle changes empower diabetes patients to improve their health and confidence in self-care.

The Sinovac-CoronaVac vaccine significantly reduces COVID-19 mortality in patients with schizophrenia, highlighting an increased importance of vaccination.

With little evidence on vaccine coverage for people living with HIV, researchers explored pneumococcal vaccine rates between 2014 and 2023.

Pharmacists enhance diabetes care by educating patients on insulin management, ensuring safe practices, and tailoring regimens for better glycemic control.

This December 2025 order is an extension of HHS’ recommendation to reconsider marijuana as a Schedule III medication in 2023.